Department of Medicine, College of Nursing at Augusta University, Augusta, GA, U.S.A.
Vascular Biology Center, Medical College of Georgia, College of Nursing at Augusta University, Augusta, GA, U.S.A.
Clin Sci (Lond). 2022 Mar 18;136(5):309-321. doi: 10.1042/CS20220031.
Prostaglandin D2 (PGD2) released from immune cells or other cell types activates its receptors, D prostanoid receptor (DP)1 and 2 (DP1 and DP2), to promote inflammatory responses in allergic and lung diseases. Prostaglandin-mediated inflammation may also contribute to vascular diseases such as abdominal aortic aneurysm (AAA). However, the role of DP receptors in the pathogenesis of AAA has not been systematically investigated. In the present study, DP1-deficient mice and pharmacological inhibitors of either DP1 or DP2 were tested in two distinct mouse models of AAA formation: angiotensin II (AngII) infusion and calcium chloride (CaCl2) application. DP1-deficient mice [both heterozygous (DP1+/-) and homozygous (DP1-/-)] were protected against CaCl2-induced AAA formation, in conjunction with decreased matrix metallopeptidase (MMP) activity and adventitial inflammatory cell infiltration. In the AngII infusion model, DP1+/- mice, but not DP1-/- mice, exhibited reduced AAA formation. Interestingly, compensatory up-regulation of the DP2 receptor was detected in DP1-/- mice in response to AngII infusion, suggesting a potential role for DP2 receptors in AAA. Treatment with selective antagonists of DP1 (laropiprant) or DP2 (fevipiprant) protected against AAA formation, in conjunction with reduced elastin degradation and aortic inflammatory responses. In conclusion, PGD2 signaling contributes to AAA formation in mice, suggesting that antagonists of DP receptors, which have been extensively tested in allergic and lung diseases, may be promising candidates to ameliorate AAA.
前列腺素 D2 (PGD2) 从免疫细胞或其他细胞类型释放出来,激活其受体,D 前列腺素受体 (DP)1 和 2 (DP1 和 DP2),以促进过敏和肺部疾病中的炎症反应。前列腺素介导的炎症也可能导致血管疾病,如腹主动脉瘤 (AAA)。然而,DP 受体在 AAA 发病机制中的作用尚未得到系统研究。在本研究中,DP1 缺陷小鼠和 DP1 或 DP2 的药理学抑制剂在两种不同的 AAA 形成小鼠模型中进行了测试:血管紧张素 II (AngII) 输注和氯化钙 (CaCl2) 应用。DP1 缺陷小鼠(杂合子 (DP1+/-) 和纯合子 (DP1-/-))均能预防 CaCl2 诱导的 AAA 形成,同时 MMP 活性和外膜炎症细胞浸润减少。在 AngII 输注模型中,DP1+/- 小鼠,但不是 DP1-/- 小鼠,AAA 形成减少。有趣的是,在 AngII 输注时,DP1-/- 小鼠中检测到 DP2 受体的代偿性上调,表明 DP2 受体在 AAA 中可能具有潜在作用。选择性 DP1 拮抗剂 (laropiprant) 或 DP2 拮抗剂 (fevipiprant) 的治疗可预防 AAA 形成,同时减少弹性蛋白降解和主动脉炎症反应。总之,PGD2 信号在小鼠中导致 AAA 形成,表明 DP 受体拮抗剂在过敏和肺部疾病中已得到广泛测试,可能是改善 AAA 的有前途的候选药物。